Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME: Secukinumab vs Fumaderm in Plaque Psoriasis
NCT02474082Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in plaque psoriasis, sponsored by Novartis. Started Apr 2015; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02474082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02474082.